Floatz logo

109 assets in Sarcoma

Therapeutic assets addressing Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Sarcoma
National Cancer Institute (NCI)P1/2CC (44)
[203pb]pb-psv359
Sarcoma
Perspective TherapeuticsP1/2CC (43)
[212pb]pb-psv359
Sarcoma
Perspective TherapeuticsP1/2CC (43)
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo-
Sarcoma
STORM Therapeutics LTDP1/2CC (43)
cd146/her2 car-t cells
Sarcoma
Essen BiotechP1/2CC (43)
Ebnk-001
Sarcoma
Essen BiotechP1/2CC (43)
gd2-cart01
Sarcoma
Bambino Gesù Hospital and Research InstituteP1/2CC (43)
htl0039732 capsules
Sarcoma
Cancer Research UKP1/2CC (43)
Interleukin-15
Sarcoma
Essen BiotechP1/2CC (43)
Sarcoma-Specific Car-T Cells
Sarcoma
Shenzhen Geno-Immune Medical InstituteP1/2CC (43)
Solnerstotug
Sarcoma
Sensei Biotherapeutics, Inc.P1/2CC (43)
Stc-15
Sarcoma
STORM Therapeutics LTDP1/2CC (43)
t3011
Sarcoma
ImmVira Pharma Co. LtdP1/2CC (43)
Toripalimab
Sarcoma
STORM Therapeutics LTDP1/2CC (43)
zl-6201
Sarcoma
Zai Lab (Shanghai) Co., Ltd.P1CC (43)
Ganciclovir
Sarcoma
Gene Surgery LLCP1CC (42)
PRT1419
Sarcoma
Prelude TherapeuticsP1CC (42)
prt2527
Sarcoma
Prelude TherapeuticsP1CC (42)
prt3645
Sarcoma
Prelude TherapeuticsP1CC (42)
Stimotimagene Copolymerplasmid
Sarcoma
Gene Surgery LLCP1CC (42)
Alpelisib
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
Anastrozole
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
Apg-5918
Sarcoma
Ascentage Pharma Group Inc.P1C (39)
b7-h3cart
Sarcoma
Stanford UniversityP1C (39)
cct303-406
Sarcoma
Shanghai PerHum Therapeutics Co., Ltd.P1C (39)
Cobimetinib
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
crd3874
Sarcoma
Memorial Sloan Kettering Cancer CenterP1C (39)
ds-2243a
Sarcoma
Daiichi SankyoP1C (39)
Emunkitug
Sarcoma
HiFiBiO TherapeuticsP1C (39)
Fulvestrant
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
GD2-SADA
Sarcoma
Y-mAbs TherapeuticsP1C (39)
Hyaluronidase Zzxf
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
Idov-Immune
Sarcoma
ViroMissile, Inc.P1C (39)
MGC026
Sarcoma
MacroGenicsP1C (39)
Niraparib
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
Ny-Eso-1 Tcr Redirected Autologous T Cell Product
Sarcoma
Centre Hospitalier Universitaire VaudoisP1C (39)
okn4395
Sarcoma
EpkinP1C (39)
Olaparib
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
Pepticrad-1
Sarcoma
Valo Therapeutics OyP1C (39)
Pertuzumab
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
pf-07263689
Sarcoma
PfizerP1C (39)
Slv-154
Sarcoma
Solve TherapeuticsP1C (39)
Somatotropin (Ox), 127-L-Leucine-
Sarcoma
German Cancer Research CenterP1C (39)
Sti-1386
Sarcoma
Sorrento Therapeutics, Inc.P1C (39)
<Sup>177</Sup>Lu-Dota
Sarcoma
Y-mAbs TherapeuticsP1C (39)
Super1 Tcr-T
Sarcoma
Guangzhou FineImmune Biotechnology Co., LTD.P1C (39)
Trastuzumab Emtansine
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
Turalio
Sarcoma
National Cancer Institute (NCI)P1C (39)
Vemurafenib
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
Vismodegib
Sarcoma
OHSU Knight Cancer InstituteEarly P1C (39)
Showing 51 to 100 of 109 assets
PreviousPage 2 of 3Next